An in vitro, light responsive retina model for better prediction of in vivo outcomes.
Retinal cell death leads to loss of vision in complex, multigenic age-related eye diseases such as age-related macular degeneration (AMD), and monogenic eye diseases such as retinitis pigmentosa, Stargardt disease, Usher’s syndrome and Leber congenital amaurosis.
Inherited retinopathies affect 1 in 2,000-3,000 individuals. There are over 250 genes in the human genome associated with these diseases.
Newcells Biotech’s iPSC technology generates functional retinal organoids and their companion retinal pigment epithelium (RPE) to model the healthy human retina, that we can engineer to contain retinopathy-specific mutations and enable disease modelling.
Our iPSC-derived retinal organoids and RPE allow you to get better insights into retinal disease pathogenesis.
Cone photoreceptor cells labelled with anti-Opsin (Red/Green) antibody at 150 days of differentiation.
Drug Safety and Efficacy Testing
Drug-induced retinal toxicity is a relatively rare occurrence but with potential life-changing impact for patients.
Existing in vitro pre-clinical models for testing drug safety and efficacy are poor representations of the complex human retina.
Newcells Biotech’s iPSC-derived retinal organoids and companion RPE have a distinctive advantage over existing in vitro models; they are more accurate at in vitro to in vivo extrapolation (IVIVE).
Our iPSC-derived retinal organoids and RPE enable screening of new therapies, including gene therapies, for safety and efficacy.
Rod photoreceptor cells labelled with anti-Rhodopsin and horizontal cells labelled with anti-Prox1 antibodies at 150 days of differentiation.
Newcells Biotech Retina Model
Accelerate your research with a reliable and consistent, light responsive model of diseased and healthy retinal tissue.
Using organoids could signifcantly reduce or even eliminate the need for animal experiments for the retina.